| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.087 | 0.03 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.03 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.082 | 0.03 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.04 |